1876 related articles for article (PubMed ID: 16098456)
41. New developments in the treatment of postmenopausal breast cancer.
Howell A
Trends Endocrinol Metab; 2005 Nov; 16(9):420-8. PubMed ID: 16213745
[TBL] [Abstract][Full Text] [Related]
42. Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor.
Markopoulos C
Surg Oncol; 2008 Aug; 17(2):113-28. PubMed ID: 18178077
[TBL] [Abstract][Full Text] [Related]
43. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
44. Extended adjuvant endocrine therapy of early breast cancer.
Chowdhury S; Ellis P
Curr Med Res Opin; 2005 Dec; 21(12):1985-95. PubMed ID: 16368050
[TBL] [Abstract][Full Text] [Related]
45. Advances in adjuvant endocrine therapy for postmenopausal women.
Lin NU; Winer EP
J Clin Oncol; 2008 Feb; 26(5):798-805. PubMed ID: 18258989
[TBL] [Abstract][Full Text] [Related]
46. [Adjuvant treatment of breast cancer by concomitant hormonotherapy and radiotherapy: state of the art].
Azria D; Lemanski C; Zouhair A; Gutowski M; Belkacémi Y; Dubois JB; Romieu G; Ozsahin M
Cancer Radiother; 2004 Jun; 8(3):188-96. PubMed ID: 15217586
[TBL] [Abstract][Full Text] [Related]
47. Clinical differences among the aromatase inhibitors.
Ligibel JA; Winer EP
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):473S-9S. PubMed ID: 12538503
[TBL] [Abstract][Full Text] [Related]
48. Adjuvant endocrine therapy for early breast cancer.
Andreetta C; Smith I
Cancer Lett; 2007 Jun; 251(1):17-27. PubMed ID: 17150303
[TBL] [Abstract][Full Text] [Related]
49. Aromatase inhibitors--extending the benefits of adjuvant therapy beyond tamoxifen.
Smith IE
Breast; 2004 Dec; 13 Suppl 1():S3-9. PubMed ID: 15585377
[TBL] [Abstract][Full Text] [Related]
50. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
51. Anastrozole for breast cancer: recent advances and ongoing challenges.
Buzdar AU
Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927
[TBL] [Abstract][Full Text] [Related]
52. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial.
Hilsenbeck SG; Osborne CK
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1049s-1055s. PubMed ID: 16467123
[TBL] [Abstract][Full Text] [Related]
53. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
[TBL] [Abstract][Full Text] [Related]
54. Current controversies in extended adjuvant endocrine therapy for early breast cancer.
Snoj N; Paridaens R; Cufer T
Curr Opin Oncol; 2008 Nov; 20(6):627-33. PubMed ID: 18841043
[TBL] [Abstract][Full Text] [Related]
55. Adjuvant endocrine therapy in postmenopausal breast cancer.
Ingle JN
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):480S-5S. PubMed ID: 12538504
[TBL] [Abstract][Full Text] [Related]
56. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
[TBL] [Abstract][Full Text] [Related]
57. Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors.
Fentiman IS
Int J Clin Pract; 2006 Jun; 60(6):689-93. PubMed ID: 16805754
[TBL] [Abstract][Full Text] [Related]
58. Aromatase inhibitors in the treatment of early and advanced breast cancer.
Joensuu H; Ejlertsen B; Lønning PE; Rutqvist LE
Acta Oncol; 2005; 44(1):23-31. PubMed ID: 15848903
[TBL] [Abstract][Full Text] [Related]
59. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Therasse P; Palmer MJ; Pater JL
N Engl J Med; 2003 Nov; 349(19):1793-802. PubMed ID: 14551341
[TBL] [Abstract][Full Text] [Related]
60. Early recurrence risk: aromatase inhibitors versus tamoxifen.
Bria E; Carlini P; Cuppone F; Vaccaro V; Milella M; Cognetti F
Expert Rev Anticancer Ther; 2010 Aug; 10(8):1239-53. PubMed ID: 20735310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
